MorphoSys AG
21.7.2021 22:22:12 CEST | ACCESS Newswire | Press release
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Stagwell (STGW) Appoints Nagmeh Taheri to Chief Growth Officer, Media & Commerce for Stagwell Europe16.10.2026 13:40:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 16, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the appointment of NagmehTaheri as Chief Growth Officer, Media & Commerce for Stagwell Europe, effective November 18, 2026. Reporting into James Denton-Clark, Chief Growth & Client Officer of Stagwell Europe, Taheri will oversee new business efforts across the European region for the Media & Commerce segment at Stagwell working specifically with sister media agencies Goodstuff and Stagwell Media. Taheri brings over 25 years of experience driving growth across some of the world's leading marketing holding companies, including WPP, Dentsu, Publicis Groupe, IPG and Omnicom. Widely recognised as one of the UK's foremost new business leaders, Taheri was ranked No. 1 in Campaign's UK Media New Business rankings in 2022 and 2024 and No. 3 in 2025. Throughout her career, she has built and led growth functions that have transformed how agency
Datavault AI Highlights Data Futures Platform Patent Amid Tokenized Stock Exemption15.10.2026 19:25:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / October 15, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its Method and System for Data Futures Platform patent application (U.S. Patent Application No. 17/441,847), and highlighted the relevance of the disclosed technology to a significant development in the regulatory landscape for tokenized securities. On September 17, 2026, the U.S. Securities and Exchange Commission announced a temporary, conditional "Innovation Exemption" intended to facilitate on-chain trading of certain tokenized National Market System stocks through qualifying Tokenized Securities Venues. The action represents a meaningful regulatory development for market participants exploring blockchain-based securities infrastructure, subject
Valsoft's TAG Software Group Acquires Positive Solutions, a UK Provider of Healthcare and Pharmacy Software15.10.2026 17:00:00 CEST | Press release
MONTRÉAL, QC / ACCESS Newswire / October 15, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Canadian company specializing in the acquisition and long-term development of vertical market software businesses, today announced the acquisition of Positive Solutions Limited ("Positive Solutions"), a UK-based provider of pharmacy management and point-of-sale software for community pharmacies. The acquisition was completed through TAG Software Group, a wholly owned subsidiary of Valsoft. Founded in 1993 and headquartered in Adlington, UK, Positive Solutions provides integrated software that community pharmacies use to dispense medicine and run their retail operations. Its core products, Analyst PMR (patient medication record) and Analyst EPoS (electronic point of sale), support pharmacies ranging from single-site locations to large corporations. The company serves more than 2,500 sites across England, Scotland, and Wales. With this acquisition, TAG Software Group strengthens Valsoft's presence
OMP and Eastman Show Decision Velocity in Practice at Gartner Supply Chain Planning Summit 202615.10.2026 15:00:00 CEST | Press release
ATLANTA, GA / ACCESS Newswire / October 15, 2026 / OMP, a leader in AI-powered supply chain planning, is bringing Eastman to the Gartner Supply Chain Planning Summit 2026 in Denver, CO (November 2-3) to showcase decision velocity in practice. The global specialty materials company will show how it connected its long-term, mid-term, and short-term planning horizons into one cycle. Eastman on connecting its planning horizons In a session at the summit, Sachin Kothari, Manager IBP Excellence at Eastman, and Abhi Patel, Chief Business Operations Officer at OMP, will explain how Eastman moved from three planning horizons that each ran on their own schedule to one connected cycle linking long-, mid-, and short-term planning on a shared view of the value chain. The session also covers what got in the way of the shift and closes with the impact Eastman measured, along with recommendations for supply chain leaders whose planning still relies on handoffs. Meet OMP and explore planning transforma
Innodata to Report Third Quarter 2026 Results15.10.2026 14:05:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / October 15, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Third Quarter 2026 results after the market closes on Thursday, November 5, 2026. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are:(+1) 833 296 5777 North America, Toll Free(+44) 808 196 8935 United Kingdom(+1) 206 407 3228 InternationalParticipant Access Code 730 768 717 For Replay: (+1) 833 309 1852 North America-Toll Free(+44) 800 007 4044 United Kingdom(+1) 929 828 5978 InternationalAccess Code 730 768 717 Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom